yes, excellent! :)and you might like this recent 2024 one that...

yes, excellent!
and you might like this recent 2024 one that does a deep dive across the MTOR inhibitor and BBB space,
and delves into the myriads of cascade effects across the various signalling pathways....

https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1366061/full

I'd been looking around for anything related to monepantel-specific mechanistic actions in various NDs -- and thinking about the pre-clinicals -- but MPL is too new in this space, but from everything in that article, MPL looks to be the perfect sulphone bullet to trigger treatment benefit.
The first line of conclusion was compelling;
mTOR inhibition modulates a plethora of pathologies associated with AD.

The first line of the article triggered a memory connection for monepantel and pre-clinicals;
Traditionally, pharmacological mammalian/mechanistic targets of rapamycin (mTOR) kinase inhibitors have been used during transplantation and tumor treatment.
I'd looked everywhere except in our own backyard... on our own work on cancer and autophagy,
and a mass of pre-clinical commentary worth viewing again for those interested...
The details of which our CSO will be completely across, and perhaps some indications for her current work..

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315739/



cheers,
Ice